Dermot S. O'CAllaghan

Dermot S. O'CAllaghan

Auto-generated profile, based on publicly available information

Dermot S. O'CAllaghan

Centre for Lung Health, Mater Misericordiae University Hospital, Dublin, Ireland

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2010 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
MHM Humbert
M Humbert
OSO Sitbon
O Sitbon
AYA Yaïci
A Yaïci
David MontaniDavid Montani
David Montani
DOD S O'Callaghan
D S O'Callaghan
FNFrench Pulmonary Arterial Hypertension Network
French Pulmonary Arterial Hypertension Network
Pulmonary arterial hypertension (PAH) is a progressive, fatal disease.We studied 674 consecutive adult patients who were prospectively enrolled in the French PAH registry (121 incident and 553 prevalent cases). Two survival analyses were performed. First, the cohort of 674 patients was followed for 3 yrs after study entry and survival rates described. Then, we focused on the subset with incident idiopathic, familial and anorexigen-associated PAH (n = 56) combined with prevalent patients who were diagnosed <3 yrs prior to study entry (n = 134).In the cohort of 674 patients, 1-, 2-, and 3-yr survival rates were 87% (95% CI 84–90), 76% (95% CI 73–80), and 67% (95% CI 63–71), respectively. In prevalent idiopathic, familial and anorexigen-associated PAH, 1-, 2-, and 3-yr survival rates were higher than in incident patients (p = 0.037). In the combined cohort of patients with idiopathic, familial and anorexigen-associated PAH, multivariable analysis showed that survival could be estimated by means of a novel risk-prediction equation using patient sex, 6-min walk distance, and cardiac output at diagnosis.This study highlights survivor bias in prevalent cohorts of PAH patients. Survival of idiopathic, familial and anorexigen-associated PAH can be characterised by means of a novel risk-prediction equation using patients' characteristics at diagnosis.

1 May 2012 in Circulation
Verified
Journal Article
Closed access
PDF file
David MontaniDavid Montani
David Montani
EBEmmanuel Bergot
Emmanuel Bergot
SGSven Günther
Sven Günther
LSLaurent Savale
Laurent Savale
ABAnne Bergeron Bergeron
Anne Bergeron Bergeron
MHMarc Humbert
Marc Humbert
Background—: The French pulmonary hypertension (PH) registry allows the survey of epidemiological trends. Isolated cases of precapillary PH have been reported in patients who have chronic myelogenous leukemia treated with the tyrosine kinase inhibitor dasatinib. Methods and Results—: This study was designed to describe incident cases of dasatinib-associated PH reported in the French PH registry. From the approval of dasatinib (November 2006) to September 30, 2010, 9 incident cases treated by dasatinib at the time of PH diagnosis were identified. At diagnosis, patients had moderate to severe precapillary PH with functional and hemodynamic impairment. No other incident PH cases were exposed to other tyrosine kinase inhibitors at the time of PH diagnosis. Clinical, functional, or hemodynamic improvements were observed within 4 months of dasatinib discontinuation in all but 1 patient. Three patients required PH treatment with endothelin receptor antagonist (n=2) or calcium channel blocker (n=1). After a median follow-up of 9 months (min-max 3–36), the majority of patients did not demonstrate complete clinical and hemodynamic recovery, and no patients reached a normal value of mean pulmonary artery pressure (≤20 mm Hg). Two patients (22%) died at follow-up (1 of unexplained sudden death and 1 of cardiac failure in the context of septicemia, respectively, 8 and 12 months after dasatinib withdrawal). The lowest estimate of incident PH occurring in patients exposed to dasatinib in France was 0.45%. Conclusions—: Dasatinib may induce severe precapillary PH fulfilling the criteria of pulmonary arterial hypertension, thus suggesting a direct and specific effect of dasatinib on pulmonary vessels. Improvement is usually observed after withdrawal of dasatinib.

7 July 2011 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
FPFlorence Parent
Florence Parent
DBDora Bachir
Dora Bachir
JIJocelyn Inamo
Jocelyn Inamo
FLFrançois Lionnet
François Lionnet
FDFrançoise Driss
Françoise Driss
GSGerald Simonneau
Gerald Simonneau
The prevalence and characteristics of pulmonary hypertension in adults with sickle cell disease have not been clearly established.

15 April 2010 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
BGBarbara Girerd
Barbara Girerd
David MontaniDavid Montani
David Montani
FCFlorence Coulet
Florence Coulet
BSBenjamin Sztrymf
Benjamin Sztrymf
AYAzzeddine Yaici
Azzeddine Yaici
MHMarc Humbert
Marc Humbert
Rationale: Activin A receptor type II-like kinase-1 (ACVRL1, also known as ALK1) mutation is a cause of hereditary hemorrhagic telangiectasia (HHT) and/or heritable pulmonary arterial hypertension (PAH). Objectives: To describe the characteristics of patients with PAH carrying an ACVRL1 mutation. Methods: We reviewed clinical, functional, and hemodynamic characteristics of 32 patients with PAH carrying an ACVRL1 mutation, corresponding to 9 patients from the French PAH Network and 23 from literature analysis. These cases were compared with 370 patients from the French PAH Network (93 with a bone morphogenetic protein receptor type 2 [BMPR2] mutation and 277 considered as idiopathic cases without identified mutation). Distribution of mutations in the ACVRL1 gene in patients with PAH was compared with the HHT Mutation Database. Measurements and Main Results: At diagnosis, ACVRL1 mutation carriers were significantly younger (21.8 ± 16.7 yr) than BMPR2 mutation carriers and noncarriers (35.7 ± 14.9 and 47.6 ± 16.3 yr, respectively; P < 0.0001). In seven of the nine patients from the French PAH Network, PAH diagnosis preceded manifestations of HHT. ACVRL1 mutation carriers had better hemodynamic status at diagnosis, but none responded to acute vasodilator challenge and they had shorter survival when compared with other patients with PAH despite similar use of specific therapies. ACVRL1 mutations in exon 10 were more frequently observed in patients with PAH, as compared with what was observed in the HHT Mutation Database (33.3 vs. 5%; P < 0.0001). Conclusions: ACVRL1 mutation carriers were characterized by a younger age at PAH diagnosis. Despite less severe initial hemodynamics and similar management, these patients had worse prognosis compared with other patients with PAH, suggesting more rapid disease progression.

1 December 2010 in Journal of Thoracic Oncology
Verified
Journal Article
Open access
PDF file
DODermot S. O'CAllaghan
Dermot S. O'CAllaghan
DODearbhaile O'DOnnell
Dearbhaile O'DOnnell
FOFinbarr O'COnnell
Finbarr O'COnnell
KOKenneth J. O'BYrne
Kenneth J. O'BYrne
The link between chronic immune activation and tumorigenesis is well established. Compelling evidence has accumulated that histologic assessment of infiltration patterns of different host immune response components in non-small cell lung cancer specimens helps identify different prognostic patient subgroups. This review provides an overview of recent insights gained in the understanding of the role played by chronic inflammation in lung carcinogenesis. The usefulness of quantification of different populations of lymphocytes, natural killer cells, macrophages, and mast cells within the tumor microenvironment in non-small cell lung cancer is also discussed. In particular, the importance of assessment of inflammatory cell microlocalization within both the tumor islet and surrounding stromal components is emphasized.

1 August 2013 in Chest
Verified
Journal Article
Closed access
GGGilles Garcia
Gilles Garcia
AMAntoine Magnan
Antoine Magnan
RCRaphaël Chiron
Raphaël Chiron
CCCécile Contin-Bordes
Cécile Contin-Bordes
PBPatrick Berger
Patrick Berger
MHMarc Humbert
Marc Humbert